JANX
Janux Therapeutics Inc
NASDAQ · Biotechnology
$13.07
+0.89 (+7.31%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 11.85M | 8.30M | 133.28M | 135.69M | 126.98M |
| Net Income | -77,205,731 | -48,676,117 | 15.76M | 14.63M | 16.31M |
| EPS | — | — | — | — | — |
| Profit Margin | -651.6% | -619.0% | 11.8% | 10.8% | 12.8% |
| Rev Growth | +42.8% | +42.8% | +7.4% | +1.9% | +5.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 232.88M | 248.01M | 256.79M |
| Total Equity | — | — | 650.57M | 596.16M | 658.27M |
| D/E Ratio | — | — | 0.36 | 0.42 | 0.39 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -108,302,149 | -72,074,985 | 19.77M | 20.57M | 19.85M |
| Free Cash Flow | — | — | 15.72M | 20.68M | 20.15M |